LT3001 not checked
Shanghai Pharmaceuticals Holding Co., Ltd
FollowEvery change as it happens, and a Monday email
Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Drug: LT3001 Drug:high dose Administered by intravenous infusion.”In the company’s words, NCT07754825 on ClinicalTrials.gov
- Tested for
- Acute Ischemic Stroke (2 trials)
- Main trialPhase 2
- “This phase II clinical study is designed to evaluate the safety and efficacy of LT3001 in the treatment of acute ischemic stroke”In the company’s words, NCT05686642 on ClinicalTrials.gov
Other drugs for Acute Ischemic Stroke
- Neuroncell-EXCytopeutics Sdn. Bhd. · Phase 2/3
- DM199DiaMedica Therapeutics Inc · Phase 2/3
- SP-8203Shin Poong Pharmaceutical Co. Ltd. · Phase 3
- SHPL-49Shanghai Hutchison Pharmaceuticals Limited · Phase 3
- RhTNK-tPACSPC · Phase 3
- SovateltidePharmazz, Inc. · Phase 3
Coming up2
- 10 DecPhase 2 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 10 Dec 2026 | Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke | |
| Phase 2Not yet recruiting | 31 Dec 2027 | A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026